Biotech Pharmaceutical Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Joint Venture, Private, Subsidiary
- Established
- 2000-08-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.biotechplc.com
Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal Cancer
Phase 3
- Conditions
- Interventions
- First Posted Date
- 2010-02-24
- Last Posted Date
- 2015-10-30
- Lead Sponsor
- Biotech Pharmaceutical Co., Ltd.
- Target Recruit Count
- 480
- Registration Number
- NCT01074021
- Locations
- 🇨🇳
Fujian Medical University Union Hospital, Fuzhou, Fujian, China
🇨🇳Wuhan Union Hospital, Wuhan, Hubei, China
🇨🇳The Affiliated Renji Hosptial of ShanghaiJiao Tong University, Shanghai, China
Nimotuzumab in Combination With Cisplatin and Docetaxel for Patients With Advanced Non-small Cell Lung Cancer
- First Posted Date
- 2009-09-29
- Last Posted Date
- 2015-08-19
- Lead Sponsor
- Biotech Pharmaceutical Co., Ltd.
- Registration Number
- NCT00985998
- Locations
- 🇨🇳
Cancer Institute & Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
Nimotuzumab Plus Docetaxel in Chemotherapy-Refractory/Resistant Patients With Advanced Non-Small-Cell Lung Cancer
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2009-09-23
- Last Posted Date
- 2015-08-27
- Lead Sponsor
- Biotech Pharmaceutical Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT00983047
- Locations
- 🇨🇳
Peking University School of Oncology, Beijing Institute for Cancer Research, Beijing Cancer Hospital, Beijing, China
Nimotuzumab in Combination With Chemoradiation for Esophageal Cancer
- First Posted Date
- 2009-07-31
- Last Posted Date
- 2015-08-19
- Lead Sponsor
- Biotech Pharmaceutical Co., Ltd.
- Target Recruit Count
- 11
- Registration Number
- NCT00950417
- Locations
- 🇨🇳
Fudan University Cancer Hospital, Shanghai, Shanghai, China
© Copyright 2024. All Rights Reserved by MedPath